[PDF][PDF] Proteogenomic characterization reveals therapeutic vulnerabilities in lung adenocarcinoma
…, M Wiznerowicz, ZH Gümüş, RR Veluswamy… - Cell, 2020 - cell.com
To explore the biology of lung adenocarcinoma (LUAD) and identify new therapeutic
opportunities, we performed comprehensive proteogenomic characterization of 110 tumors and …
opportunities, we performed comprehensive proteogenomic characterization of 110 tumors and …
The global burden of lung cancer: current status and future trends
A Leiter, RR Veluswamy, JP Wisnivesky - Nature Reviews Clinical …, 2023 - nature.com
Lung cancer is the leading cause of cancer-related death worldwide. However, lung cancer
incidence and mortality rates differ substantially across the world, reflecting varying patterns …
incidence and mortality rates differ substantially across the world, reflecting varying patterns …
[HTML][HTML] Limited resection versus lobectomy for older patients with early-stage lung cancer: impact of histology
RR Veluswamy, N Ezer, G Mhango… - Journal of Clinical …, 2015 - ncbi.nlm.nih.gov
Purpose Limited resection has been increasingly used in older patients with stage IA lung
cancer. However, the equivalency of limited resection versus lobectomy according to histology …
cancer. However, the equivalency of limited resection versus lobectomy according to histology …
[HTML][HTML] KRAS G12C–mutant non–small cell lung cancer: biology, developmental therapeutics, and molecular testing
R Veluswamy, PC Mack, J Houldsworth… - The Journal of Molecular …, 2021 - Elsevier
Mutation in the gene that encodes Kirsten rat sarcoma viral oncogene homolog (KRAS) is
the most common oncogenic driver in advanced non–small cell lung cancer, occurring in …
the most common oncogenic driver in advanced non–small cell lung cancer, occurring in …
An IL-4 signalling axis in bone marrow drives pro-tumorigenic myelopoiesis
…, DB Doroshow, NC Rohs, JE Gomez, R Veluswamy… - Nature, 2024 - nature.com
Myeloid cells are known to suppress antitumour immunity 1 . However, the molecular
drivers of immunosuppressive myeloid cell states are not well defined. Here we used single-cell …
drivers of immunosuppressive myeloid cell states are not well defined. Here we used single-cell …
[HTML][HTML] Outcomes after stereotactic body radiotherapy versus limited resection in older patients with early-stage lung cancer
N Ezer, RR Veluswamy, G Mhango… - Journal of Thoracic …, 2015 - Elsevier
Background: Limited resection and stereotactic body radiotherapy (SBRT) have emerged as
treatment options for older patients with early-stage non–small-cell lung cancer (NSCLC), …
treatment options for older patients with early-stage non–small-cell lung cancer (NSCLC), …
Comparative effectiveness of robotic-assisted surgery for resectable lung cancer in older patients
RR Veluswamy, SAW Brown, G Mhango, K Sigel… - Chest, 2020 - Elsevier
Background Robotic-assisted surgery (RAS) is a novel surgical approach increasingly used
for patients with non-small cell lung cancer (NSCLC). However, data comparing the …
for patients with non-small cell lung cancer (NSCLC). However, data comparing the …
[HTML][HTML] Prognostic value of immune cells in the tumor microenvironment of early-stage lung cancer: a meta-analysis
S Tuminello, R Veluswamy, W Lieberman-Cribbin… - Oncotarget, 2019 - ncbi.nlm.nih.gov
Background: Early-stage non-small cell lung cancer (NSCLC) patients carry significant risk of
recurrence post-surgery. In-depth characterization of the immune tumor microenvironment (…
recurrence post-surgery. In-depth characterization of the immune tumor microenvironment (…
[HTML][HTML] PD-L1 as a prognostic biomarker in surgically resectable non-small cell lung cancer: a meta-analysis
S Tuminello, D Sikavi, R Veluswamy… - Translational Lung …, 2020 - ncbi.nlm.nih.gov
Background PD-L1 tumor expression has been associated with poor prognosis in a variety
of solid tumors, including lung cancer, and represents a validated target for immune …
of solid tumors, including lung cancer, and represents a validated target for immune …
Analysis of real-world data to investigate the impact of race and ethnicity on response to programmed cell death-1 and programmed cell death-ligand 1 inhibitors in …
…, T Prentice, S Newman, R Veluswamy… - The …, 2021 - academic.oup.com
Background Racial disparities among clinical trial participants present a challenge to
assess whether trial results can be generalized into patients representing diverse races and …
assess whether trial results can be generalized into patients representing diverse races and …